Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)
Kevin Kalinsky(Emory University), Lajos Pusztai(Yale University), Danika L. Lew, Jean‐Yves Pierga(Université Paris Cité), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), S. Shak(Einstein Medical Center Philadelphia), Julie R. Gralow(American Society of Clinical Oncology), Jean-Marc Ferrero(Centre Antoine Lacassagne), Emilio Alba(Hospital Clínico Universitario Virgen de la Victoria), In Hae Park(National Cancer Center), Anne F. Schott(University of Michigan), Priyanka Sharma(Chandigarh University), Nancy U. Lin(Dana-Farber Cancer Institute), Lori J. Goldstein(Shaanxi Research Association for Women and Family), Kyung Hae Jung(University of Ulsan), Kathy S. Albain(Loyola University Chicago), Edith A. Perez(Unknown), Manuel Ramos Vasquez(Centro Oncológico de Galicia), Daniel F. Hayes(University of Michigan–Ann Arbor), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Stephen Chia(BC Cancer Agency), William E. Barlow(Cancer Research And Biostatistics), Suzette Delaloge(Institut Gustave Roussy), Miguel Martín(Hospital General Universitario Gregorio Marañón), Subkhbinder Dhesy-Thind(Juravinski Cancer Centre), Ana Hernandez Lluch(Hospital Clínico Universitario de Valencia), Debu Tripathy(The University of Texas MD Anderson Cancer Center), Claudia Arce-Salinas(Instituto Nacional de Cancerología), Manuel Ruíz Borrego(Hospital Universitario Virgen del Rocío), Miguel Gil Gil(Apple (Israel)), Priya Rastogi(UPMC Hillman Cancer Center), Jieling Miao, Étienne Brain(Institut Curie)
Cited by 88
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k